Bank of New York Mellon
PHAS

Bank of New York Mellon’s PhaseBio Pharmaceuticals, Inc. Common Stock PHAS Stock Holding History

Bank of New York Mellon’s Portfolio PHAS Stock Details PHAS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-34,960
Closed -$121K – 4508
2021
Q1 		$121K Sell
34,960
-2,005
-5% -$8.14K ﹤0.01% 4139
2020
Q4 		$125K Sell
36,965
-2,791
-7% -$9.99K ﹤0.01% 4049
2020
Q3 		$139K Hold
39,756
– – ﹤0.01% 3922
2020
Q2 		$182K Sell
39,756
-1,495
-4% -$6.62K ﹤0.01% 3814
2020
Q1 		$136K Buy
41,251
+5,732
+16% +$26.2K ﹤0.01% 3824
2019
Q4 		$217K Hold
35,519
– – ﹤0.01% 3894
2019
Q3 		$148K Sell
35,519
-2,650
-7% -$21.1K ﹤0.01% 3968
2019
Q2 		$501K Buy
+38,169
New +$468K ﹤0.01% 3603

Other funds holding PHAS

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
ECM
Endurant Capital Management San Mateo, California $17.4M AUM 7.38% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
JJIJ
Johnson & Johnson Innovation - JJDC New Brunswick, New Jersey $978M AUM 102.17% 1-Year Est. Return
ACM
Altium Capital Management New York $42M AUM
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return

Bank of New York Mellon's PHAS Position: Q2 2021 in Review

Bank of New York Mellon sold out of PhaseBio Pharmaceuticals, Inc. Common Stock (PHAS) in Q2 2021, closing a stake of 34,960 shares — an estimated $121K sold.

Bank of New York Mellon first reported a position in PHAS in Q2 2019 and held it in 8 quarters. The position peaked at $501K in Q2 2019. 55 funds tracked by Wall St. Rank hold PHAS as of Q2 2021.

  • Bank of New York Mellon reported no remaining PhaseBio Pharmaceuticals, Inc. Common Stock position as of Q2 2021 after selling out during the quarter.
  • Bank of New York Mellon sold 34,960 PhaseBio Pharmaceuticals, Inc. Common Stock shares in Q2 2021, an estimated $121K.
  • Bank of New York Mellon first reported a position in PhaseBio Pharmaceuticals, Inc. Common Stock in Q2 2019 and held it in 8 quarters.
  • Bank of New York Mellon's PhaseBio Pharmaceuticals, Inc. Common Stock position peaked at $501K in Q2 2019.
  • 55 funds tracked by Wall St. Rank held PhaseBio Pharmaceuticals, Inc. Common Stock as of Q2 2021.

Based on Bank of New York Mellon's 13F filing for Q2 2021, filed 11 Aug 2021.